Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.

Battin C, De Sousa Linhares A, Leitner J, Grossmann A, Lupinek D, Izadi S, Castilho A, Waidhofer-Söllner P, Grabmeier-Pfistershammer K, Stritzker J, Steinberger P

Open source

DOI: 10.1007/s00262-023-03474-8
Published: 2023 Sep
Container: Cancer immunology, immunotherapy : CII
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-023-03474-8,
  title = {Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.},
  author = {Battin C and De Sousa Linhares A and Leitner J and Grossmann A and Lupinek D and Izadi S and Castilho A and Waidhofer-Söllner P and Grabmeier-Pfistershammer K and Stritzker J and Steinberger P},
  year = {2023},
  journal = {Cancer immunology, immunotherapy : CII},
  doi = {10.1007/s00262-023-03474-8},
  url = {https://doi.org/10.1007/s00262-023-03474-8}
}

RIS

TY  - JOUR
TI  - Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
AU  - Battin C
AU  - De Sousa Linhares A
AU  - Leitner J
AU  - Grossmann A
AU  - Lupinek D
AU  - Izadi S
AU  - Castilho A
AU  - Waidhofer-Söllner P
AU  - Grabmeier-Pfistershammer K
AU  - Stritzker J
AU  - Steinberger P
PY  - 2023
JO  - Cancer immunology, immunotherapy : CII
DO  - 10.1007/s00262-023-03474-8
UR  - https://doi.org/10.1007/s00262-023-03474-8
ER  -

APA

C, B., A, D. S. L., J, L., A, G., D, L., S, I., A, C., P, W., K, G., J, S., & P, S. (2023). Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-023-03474-8

Source records

pubmed · retrieved 2026-09-25T22:31:24.420Z